Dr. Reddy's Laboratories (RDY) - Long-Term Debt to Capital

Geopolitical shifts and the exit of Western firms from sanctioned territories create new opportunities for Dr. Reddy's Laboratories (RDY), although currency fluctuations and raw material supply disruptions introduce volatility. The business relies on the production of affordable APIs and generics for the global market, capturing market share in the US and Europe. This chart shows the current share price on GURU.Markets is 0.03, while production scale and FDA requirements protect the company from smaller competitors.

To identify fundamental benchmarks, it is critical for investors to evaluate the financing structure via long-term liabilities relative to equity. This long-term debt-to-equity ratio measures the proportion of borrowed funds with a maturity exceeding one year, which enables Dr. Reddy's Laboratories (RDY) to invest effectively in the environmental modernization of plants and ESG standards while maintaining the financial stability of the business.